Prostanoid receptor EP2 as a therapeutic target.
Prostanoid receptor EP2 as a therapeutic target.
复制标题
DOI:
10.1021/jm401431x
复制
发表时间:
2014-06-12
影响因子:
7.3
通讯作者:
Ganesh T
中科院分区:
文献类型:
--
作者:
Ganesh T
Cycoloxygenase-2 (COX-2) induction is prevalent in a variety of (brain and peripheral) injury models where COX-2 levels correlate with disease progression. Thus, COX-2 has been widely explored for anti-inflammatory therapy with COX-2 inhibitors, which proved to be effective in reducing the pain and inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit to patients with chronic inflammatory neurodegenerative disease. Recently, two COX-2 drugs: rofecoxib and valdecoxib were withdrawn from the United States market due to cardiovascular side effects. Thus, future anti-inflammatory therapy could be targeted through a specific prostanoid receptor downstream of COX-2. The PGE2 receptor EP2 is emerging as a pro-inflammatory target in a variety of CNS and peripheral diseases. Here we highlight the latest developments on the role of EP2 in diseases, mechanism of activation and small molecule discovery targeted either to enhance or to block the function of this receptor.
登录
查看更多内容
DOI:
10.1016/j.jalz.2010.12.014
发表时间:
2011-07
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
Breitner JC;Baker LD;Montine TJ;Meinert CL;Lyketsos CG;Ashe KH;Brandt J;Craft S;Evans DE;Green RC;Ismail MS;Martin BK;Mullan MJ;Sabbagh M;Tariot PN;ADAPT Research Group
通讯作者:
ADAPT Research Group
影响因子:
15.9
作者:
Anderson, GD;Hauser, SD;Gregory, SA
通讯作者:
Gregory, SA
DOI:
10.1016/s1388-1981(99)00164-x
发表时间:
2000-01-17
影响因子:
4.8
作者:
Abramovitz, M;Adam, M;Metters, KM
通讯作者:
Metters, KM
影响因子:
4.8
作者:
Donnini, Sandra;Finetti, Federica;Ziche, Marina
通讯作者:
Ziche, Marina
影响因子:
14.8
作者:
Bunnage, Mark E.;Chekler, Eugene L. Piatnitski;Jones, Lyn H.
通讯作者:
Jones, Lyn H.